SP4.3 - Pancreatoduodenectomy for malignancy with concomitant arterial resection: results from the Recurrence After Whipple’s (RAW) study Free

Most centres are reluctant to perform pancreatoduodenectomy (PD) with concomitant arterial resection (AR) in patients with a cancer affecting the pancreatic head. This is because outcomes are poor and the potential benefits of an aggressive resection are unlikely to outweigh the potential risks, particularly in a patient with an aggressive tumour and limited life expectance. AR has been shown to correlate with higher rates of morbidity, reoperation and mortality, and reduced overall survival. However, AR may be justified in selected patients in specialist centres. This study aimed to compare the outcomes of PD patients who underwent AR to those who did not.

Data were extracted from the Recurrence After Whipple’s (RAW) study, a multicentre retrospective cohort study of outcomes of PD performed for pancreatic head malignancy (29 centres from eight countries, n=1484). Patients who underwent AR were identified and compared to those who did not undergo AR using the chi-squared test. The following were compared: length of stay (LoS), incidence of postpancreatectomy haemorrhage (PPH), and rates of unplanned return to theatre, 30-day readmission, 90-day mortality, and five-year survival.

Out of 1484 patients, 8.8% did not have data regarding their AR status recorded so they were excluded. Of the rest, 25 (1.8%) underwent AR. Despite the small sample size, these patients had significantly higher rates of PPH (20.0 vs 5.9%, p=0.0004) and reduced five-year survival (12.0% vs 33.1%, p=0.03).

AR should be reserved for selected PD patients in specialist units. Despite our small sample size, our multicentre study demonstrated that these patients have higher incidence of PPH and reduced long-term survival